The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption
- 1 January 2009
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 21 (1) , 18-27
- https://doi.org/10.1097/meg.0b013e32830a4f4c
Abstract
The validity of biomarkers of excessive alcohol drinking (EAD) (30 g/day or more), such as carbohydrate-deficient transferrin (CDT%), is confounded by liver disease severity. The aim was to improve the accuracy of the percentage of CDT by taking into account the presence of fibrosis and steatosis, estimated using biomarkers FibroTest and SteatoTest.Three hundred and twenty consecutive patients, 97 with alcoholic liver disease (ALD), and 223 non-ALD, were included. In ALD, 58% had advanced fibrosis and 58% had steatosis; in non-ALD, 25% had advanced fibrosis and 25% had steatosis.The mean percentage of CDT was lower in ALD with advanced fibrosis [2.4 (SE=0.2)] versus without [4.1 (0.3) P<0.0001], and lower in ALD with steatosis versus without (2.4 vs. 3.9; P=0.0007). Among non-ALD, there was no difference in the percentage of CDT according to fibrosis or steatosis. gamma-glutamyl-transpeptidase was higher in patients with advanced fibrosis or with steatosis both in ALD and non-ALD. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) was higher in ALD patients with fibrosis versus without (2.5 vs. 1.3 P<0.0001) but not in non-ALD (1.01 vs. 0.98). AST/ALT was higher in ALD patients with steatosis versus without (2.2 vs. 1.6 P=0.04) and the inverse was observed in non-ALD (0.6 vs. 1.1 P<0.0001). In the entire population the percentage of CDT, gamma-glutamyl-transpeptidase, AST/ALT was associated with EAD, the area under the receiver operating characteristic curve =0.89 (95% CI: 0.84-0.93), 0.93 (0.89-0.93) and 0.77 (0.71-0.82). An algorithm combining the percentage of CDT, FibroTest and SteatoTest permitted to obtain area under the receiver operating characteristic curve=0.92 versus 0.88 for the percentage of CDT (P=0.004) with 87.4% of patients classified correctly.Biomarkers of EAD are confounded by fibrosis and steatosis. Accuracy of the percentage of CDT is significantly increased when combined with biomarkers of fibrosis and steatosis.Keywords
This publication has 23 references indexed in Scilit:
- Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) TrialGastroenterology, 2008
- The NAFLD fibrosis scoreHepatology, 2007
- COMPARISON OF THE COMBINED MARKER GGT–CDT AND THE CONVENTIONAL LABORATORY MARKERS OF ALCOHOL ABUSE IN HEAVY DRINKERS, MODERATE DRINKERS AND ABSTAINERSAlcohol and Alcoholism, 2006
- Validity of carbohydrate‐deficient transferrin (%CDT), γ‐glutamyltransferase (γ‐GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non‐alcoholic and alcoholic originAddiction, 2005
- HIGH AST/ALT RATIO MAY INDICATE ADVANCED ALCOHOLIC LIVER DISEASE RATHER THAN HEAVY DRINKINGAlcohol and Alcoholism, 2004
- Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donorscclm, 2004
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Carbohydrate-Deficient TransferrinAlcohol, Clinical and Experimental Research, 1998
- Serum Carbohydrate‐Deficient Transferrin as a Marker of Alcohol Consumption in Patients with Chronic Liver DiseasesAlcohol, Clinical and Experimental Research, 1993
- Observer Variation in Assessment of Liver Biopsies of Alcoholic PatientsAlcohol, Clinical and Experimental Research, 1988